Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from AbbVie

The 3 Most Reliable Dividend Stocks to Buy for Years to Come

These three dividend stocks are long-term winners with dependable payouts.

Barchart

AbbVie Call Options Spike 2,599%: Tracking the Big Bet

Large institutional investors are positioning for growth as a leading biopharmaceutical firm enters the obesity market and reaches a federal agreement.

MarketBeat

Flu Season's Here—This Dividend-Payer Controls the Shot Market

With flu season in full swing, drugmakers are hoping for a short-term tailwind after a lackluster 2025. Sanofi could be the winning ticket.

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

What to Expect From AbbVie's Next Quarterly Earnings Report

AbbVie will release its fourth-quarter earnings soon, and analysts anticipate a double-digit bottom-line growth.

Barchart

2 Dividend Kings Quietly Beating the Market This Year

These two are the calm outperformers that might have been overlooked.

Barchart

3 Dividend Growth Stocks Analysts Are Upgrading for 2026

United Parcel Service, PepsiCo, and AbbVie are healthy dividend payers whose analyst trends support an outlook for price strength in 2026.

MarketBeat

3 Dividend Kings Delivering Generational Income & Market-Beating Returns

3 top-performing Dividend Kings of 2025 based on their Year-to-Date percent change.

Barchart

Read news from The Economist, FT, and more,
with one subscription

AbbVie’s (ABBV) Options Flow Implies That the Smart Money Could Be Up to Something

An intriguing quant signal combined with shifting sentiment in the derivatives market opens the possibility toward a bullish trade for ABBV stock.

Barchart

Dividend Powerhouses: 3 Blue-Chip Stocks Built for the Long Haul

AbbVie, McDonald’s, and Walmart offer growth, rising dividends, and valuation upside as investors seek blue-chip stability heading into 2026

MarketBeat

3 Dividend Aristocrats on the Edge of a Big Move

Discover three high-yield Dividend Aristocrats showing strong fundamentals and analyst support as they set up for a potential breakout.

Barchart

3 Highest-Yielding Dividend Kings To Buy, Hold, and Forget

Discover three Dividend Kings built for buy-and-forget wealth. These stable giants may quietly deliver income and growth for decades.

Barchart

Is AbbVie Stock Outperforming the Nasdaq?

AbbVie has outperformed the Nasdaq over the past year, and analysts are moderately optimistic about the stock’s prospects.

Barchart

How This 'Hidden Gold Mine' Has Beaten The Market For 30 Years

For three decades, I have watched investors chase the latest hot stock, the newest tech darling, and the most hyped IPO. Meanwhile, a sleepy corner of the market has been quietly minting fortunes.

Benzinga

Healthcare Rotation Underway: 3 Stocks Leading the Charge

Are healthcare stocks finally back in fashion? After years of underperformance, a healthcare rotation is underway, led by these three innovative drug makers.

MarketBeat

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

3 High-Growth Dividend Kings For Generations of Income - And Still Rated “Buy”

Dividend Kings with 20%+ YTD gains and strong analyst ratings show rare momentum, reliable income, and long-term stability across multiple sectors.

Barchart

3 Dividend Aristocrats Every Diversified Portfolio Should Include

Win through diversification: mix stable, income-generating Dividend Aristocrats for growth, reliability, and long-term returns.

Barchart

AbbVie Just Raised Its Dividend by 5.5%. Should You Buy ABBV Stock Here?

AbbVie just increased its dividend by 5.5%, raising the quarterly payout to $1.73 per share starting February 2026, reflecting strong confidence in its long-term growth driven by new drugs like Skyrizi and Rinvoq.

Barchart

1 High-Risk, High-Reward Way to Trade Earnings with 0DTE Options

Traders are increasingly turning to zero-days-to-expiration (0DTE) options to target fast-moving market reactions, including earnings announcements. The high leverage and compressed timeframe offered by these setups can deliver outsized returns, but those same dynamics leave little margin for error when it comes to timing and execution.

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Do Wall Street Analysts Like AbbVie Stock?

Although AbbVie has underperformed the S&P 500 Index over the past year, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.

MarketBeat

ABBV Stock: $250 May Be the New Floor After Big Q3 Earnings Beat

AbbVie beats earnings and raises guidance as Skyrizi and Rinvoq fuel growth, setting the stage for ABBV stock to hold $250 as a new floor

Benzinga

AbbVie Raises 2025 Outlook Helped By Strong Immunology Growth, Boost Dividend

AbbVie Inc. (NYSE:ABBV) reported third-quarter 2025 sales of $15.78 billion on Friday, beating the consensus of $15.59 billion.

MarketBeat

3 Pharmaceutical Growth Stocks to Buy and Hold for 10 Years

Here are three big pharma stocks that can reward patient investors with a proven history of stability, dividends, and long-term growth potential

Benzinga

Qualcomm, Aptiv, Palo Alto And A Health Care Stock On CNBC's 'Final Trades'

On CNBC's “Halftime Report Final Trades” on Tuesday, Jason Snipe, founder and chief investment officer of Odyssey Capital Advisors, said he is staying long on AbbVie Inc. (NYSE:ABBV).

Barchart

3 Dividend Kings Already Soaring and Analysts Say the Rally Isn’t Over Yet

These Companies have the Strongest Performance among the Dividend Kings

Benzinga

Amazon, AbbVie, Datadog And A Financial Stock: CNBC's 'Final Trades'

On CNBC's “Halftime Report Final Trades,” on Monday, Jim Lebenthal, partner at Cerity Partners, said AbbVie Inc (NYSE:ABBV) has gained 30% this year. The stock has a good dividend yield and also has an attractive valuation, he added.

1 2 3 4 5

People

Jim Lebenthal

36 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.